Cardiac metastasis in endometrial carcinoma: A rare case report
Rationale:
Endometrial carcinoma (EC) is a frequently occurring cancer in the female reproductive system. Nevertheless, the occurrence of cardiac metastasis in cases of EC is uncommon and represents a significant risk to women’s health.
Patient concerns:
A 58-year-old female patient experienced abnormal vaginal bleeding for over 8 months and was eventually diagnosed with stage IVC (FIGO 2023) endometrial cancer characterized by mismatch repair deficiency that had spread to the heart.
Diagnoses:
Stage IVC (FIGO 2023) mismatch repair deficiency EC with cardiac metastasis.
Interventions:
After a thorough discussion with the multidisciplinary team, a detailed noninvasive treatment strategy was established: the initial phase involved 6 cycles of induction therapy using a combination of paclitaxel and carboplatin along with tislelizumab, resulting in a partial response. This was followed by 3 cycles of maintenance therapy with tislelizumab as a standalone treatment.
Outcomes:
Following the maintenance treatment, the cardiac metastasis was entirely eliminated. The patient experienced a progression-free survival duration of 9 months.
Lessons:
For patients with EC who have metastasized to rare sites such as the heart, comprehensive management guided by multidisciplinary team consultation is crucial, as it can significantly prolong survival.
